GLPHubglpresearchhub.com
Read-only archive. GLP Research Hub is a static community record — nothing here is for sale, no account is needed, and no vote you cast is counted. Why?
287
c/trialwatch·posted 3 days ago by u/ines_castellanos

FLOW got published and nobody in here is talking about eGFR slope

Paper Long Haul ×9

Quick one. Canada here.

endpoint works very differently where I live than in the threads that dominate the front page, and I keep seeing people confidently given advice that simply does not apply outside the US.

Specifics: the route I used took 20 weeks and cost roughly what I expected. The admin was worse than the cost. The thing that would have saved me the most time was knowing which document to ask for at the start.

Happy to answer questions from anyone in the same jurisdiction.

345 up / 58 down86% upvoted30 commentsid pey1k726 Jul 2026

30 comments

21 in this archive, depth 6

best — the order this archive was captured in

u/ines_castellanos0 points·2 days ago

Is that absolute or relative risk reduction?

replysharereportpermalink
u/plateau_patrol27 points·2 days ago
okay but what dose
replysharereportpermalink
u/zaid_roos21 points·2 days ago

Small correction: the trial was 17 weeks, not 13. Does not change your point but people will quote it.

replysharereportpermalink
u/rt_shift_reggie7 points·2 days ago·edited

Edit to your parent would help — the concentration you quoted assumes one scenario and you have written another above it.

replysharereportpermalink
u/first_hundred6 points·2 days ago

the relative risk reduction in headlines is not the whole story

replysharereportpermalink
u/ines_castellanosOP3 points·2 days ago

SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/renal_outcomes_rnephro-curious-17 points·2 days ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/curious_panel_only5 points·2 days ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/receipts_or_nothingvetting4 points·2 days ago

Yeah, absolute numbers matter more than the press release.

replysharereportpermalink
u/alcohol_aversion3 points·1 days ago·edited

Small correction: the trial was 8 weeks, not 9. Does not change your point but people will quote it.

replysharereportpermalink
[removed]4 points·2 days ago

[removed by moderator]

replysharereportpermalink
u/arne_ilunga15 points·2 days ago

Small correction: the trial was 17 weeks, not 13.

Adding to this: SELECT is doing more work than the comment implies.

replysharereportpermalink
u/niels_norgaard0 points·2 days ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/nayeli_fonseca22 points·2 days ago

Crossposting this to c/bpc157 because the people who need it are not reading this community.

replysharereportpermalink
u/camila_vasquez15 points·1 days ago

SELECT reported a SURMOUNT hazard ratio but the absolute event rate is what changes clinical practice.

replysharereportpermalink
u/yara_bakken8 points·1 days ago

phase 2 is not phase 3, smaller n and shorter trial

replysharereportpermalink
u/nightowl_injector15 points·2 days ago

Mechanistically the bit that matters is SELECT. It explains most of the early profile and a decent chunk of the outcome.

replysharereportpermalink
u/ines_castellanosOP9 points·1 days ago

Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.

replysharereportpermalink
u/cesar_ivaturi0 points·1 days ago

absolute risk reduction, not relative risk reduction, that is how you decide

replysharereportpermalink
u/rina_bergstrom0 points·1 days ago

number-needed-to-treat is the house dialect

replysharereportpermalink
u/renal_outcomes_rnephro-curious8 points·1 days ago

Mechanistically the bit that matters is SELECT.

Disagree on that part. 99.2% and 99.2% on the same vial is normal.

replysharereportpermalink
Permalinked branches
Deep branches get their own page so a single reply chain can be linked and read on its own.
About c/trialwatch

Clinical trial reading group. New readouts, protocol amendments, endpoint definitions, dropout handling, and the difference between a press release and a publication. Absolute risk reduction and number-needed-to-treat are house dialect here.

34kmembers
95submissions
Nov 2023created
submissions / month, last year
Sponsored

Janoshik Analytical

Independent HPLC and mass spec. The number you get is the number they found.

janoshik.com
Sponsored

GL Biochem (Shanghai)

Custom peptides and amino acids direct from the manufacturer since 1998. ISO 9001 / cGMP. Batch COA every order.

glbiochem.net
c/trialwatch rules
  1. Press-release-only posts must be flaired Press Release until a publication exists.
  2. Give the trial name, phase, n, and primary endpoint in the body.
  3. Relative risk reduction alone is not a result. Show the absolute numbers.
  4. Independent community. Nobody here sells anything, and anyone who tries is banned.
  5. Not medical advice. Describe what you did; never prescribe to a stranger.
  6. Claims need evidence. Batch numbers, dated screenshots, independent test reports, or a citation.
  7. No referral links, discount codes or affiliate URLs. Permanent ban, no appeal.
  8. No contact handles, wallet addresses or tracking numbers — they identify people.
  9. Be recognisably decent. Disagree hard, insult nobody.
Moderators
Volunteers. Unpaid, unaffiliated, and reachable through modmail only.
Before you read on

Several compounds discussed on GLP Research Hub are sold for research use only and are not approved for human use anywhere. Nothing here is medical advice and none of it is written by your clinician. If a post reads like an instruction, treat it as a description of what one stranger did.